Antiproliferative effects of metformin in cellular models of pheochromocytoma. (1st January 2022)
- Record Type:
- Journal Article
- Title:
- Antiproliferative effects of metformin in cellular models of pheochromocytoma. (1st January 2022)
- Main Title:
- Antiproliferative effects of metformin in cellular models of pheochromocytoma
- Authors:
- Meireles, Cinthia Gabriel
Lourenço de Lima, Caroline
Martins de Paula Oliveira, Marcela
Abe da Rocha Miranda, Rafael
Romano, Lisa
Yo-Stella Brashaw, Teisha
Neves da Silva Guerra, Eliete
de Assis Rocha Neves, Francisco
Chapple, J. Paul
Simeoni, Luiz Alberto
Lofrano-Porto, Adriana - Abstract:
- Abstract: Pheochromocytomas (PCCs) are rare neuroendocrine tumors derived from adrenal medulla chromaffin cells. Malignancy and recurrence are rare but demand effective treatment. Metformin exerts antiproliferative effects in several cancer cell lines. We thus evaluated the effects of metformin on cell viability and proliferation, cellular respiration and AMPK-AKT-mTOR-HIFA proliferation pathway on a rat PCC cell line (PC12-Adh) . We then addressed metformin's effects on the AMPK-AKT-mTOR-HIFA pathway on two human primary cultures: one from a VHL-mutant PCC and other from a sporadic PCC. Metformin (20 mM) inhibited PC12-Adh cell proliferation, and decreased oxygen consumption, ATP production and proton leak, in addition to loss of mitochondrial membrane potential. Further, metformin induced AMPK phosphorylation and impaired AMPK-PI3k-AKT-mTOR pathway activation. The mTOR pathway was also inhibited in human VHL-related PCC cells, however, in an AMPK-independent manner. Metformin-induced decrease of HIF1A levels was likely mediated by proteasomal degradation. Altogether our results suggest that metformin impairs PCC cellular proliferation. Highlights: Metformin reduces rat PC12-Adh cell proliferation through AMPK activation. Metformin impairs AMPK-PI3k-AKT-mTOR pathway activation in rat PC12-Adh cells. Metformin impairs mTOR pathway independently of AMPK in VHL-mutant PCC cells. Metformin regulates HIF1A levels by increasing its proteasomal degradation.
- Is Part Of:
- Molecular and cellular endocrinology. Volume 539(2022)
- Journal:
- Molecular and cellular endocrinology
- Issue:
- Volume 539(2022)
- Issue Display:
- Volume 539, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 539
- Issue:
- 2022
- Issue Sort Value:
- 2022-0539-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-01-01
- Subjects:
- Pheochromocytoma -- Metformin -- Primary culture -- VHL -- Mitochondria -- Cellular respiration
Endocrinology -- Periodicals
Molecular biology -- Periodicals
Cytology -- Periodicals
Endocrinology -- Periodicals
Hormones -- Periodicals
Endocrinologie -- Périodiques
Cytology
Endocrinology
Molecular biology
Periodicals
573.4 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03037207 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.mce.2021.111484 ↗
- Languages:
- English
- ISSNs:
- 0303-7207
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5900.760000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24980.xml